Robert Schier
Investment Director @ Swisscanto Private Equity
Robert Schier is a Series B investor at Swisscanto Private Equity focused on Biotechnology and Health Care. Robert joined Seventure in 2010 as an Advisor to the Life Sciences Team . His time is dedicated to the coverage of German and Austrian Life Sciences community on behalf of Seventure, and to prospect new investment opportunities base there. Robert is based in Geneva.Prior to joining Seventure, Robert was Partner and Investment Director atInventages Venture Capital, a life sciences venture capital firm dedicated to nutrition, pharmaceuticals and any enabling technologies in healthcare. During his engagement with Inventages he invested in more than ten companies in Europe and the US, and served as a non-executive director on the boards of many Inventages portfolio companies.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Robert Schier invests in
Stages Robert Schier invests in
Countries Robert Schier invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (55%)
- Health Care 3 (27%)
- Life Science 2 (18%)
- Medical Device 2 (18%)
- Health Diagnostics 2 (18%)
Stage
- Series B 3 (27%)
- Series C 3 (27%)
- Series A 1 (9%)
- Funding Round 1 (9%)
- Venture - Series Unknown 1 (9%)
Country
- Switzerland 4 (36%)
- Belgium 1 (9%)
- Denmark 1 (9%)
- Germany 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | ||
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M / Series C / Nov 02, 2023 | ||
| Nagi Bioscience aims to revolutionize the way toxic and/or beneficial effects of substances are tested today, by introducing the first “Organism-on-Chip” technology. | $14.5M / Series A / Sep 28, 2023 | ||
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $24.9M / Series B / Feb 16, 2022 | ||
| Medimaps Group's mission is to design and provide medical tools to assist in the collection of quantitative information on bone microarchitecture for use in routine clinical practice.They enhance osteoporosis diagnosis by assessing the status of bone microarchitecture. They provide information to physicians to help them select the besttreatment options for their patients and monitor treatment outcomes. They are working on future products to assess bone microarchitecture for application in the dental and orthopedic fields. | $20M / Venture - Series Unknown / Dec 01, 2021 | ||
| MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | May 12, 2021 | ||
| MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse. | $29.2M / Series B / May 12, 2021 | ||
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $15.6M / Series B / Nov 06, 2020 | ||
| OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology. | $20.6M / Series B / Feb 14, 2020 | ||
| Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, with a US office in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix® WAVEsystemprovides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. Engineered around the proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix® WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment. | $8M / Series C / Sep 30, 2019 | ||
| See all 11 investments → | |||
Co-Investors
We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.
Swisscanto Private Equity Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Robert Schier
Investment Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Robert Schier invest in?
Robert Schier invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Robert Schier?
Public channels for Robert Schier include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Robert Schier last invest?
The most recent investment recorded for Robert Schier closed in May 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
